Drug intelligence / Profile preview

spiclomazine

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intraperitoneal, Intravenous, Intramuscular, Subcutaneous

Overview

Spiclomazine is a **small molecule phenothiazine derivative** with activity as an inhibitor of mutant **KRAS(G12C)** protein. It is primarily investigated in preclinical studies for its antitumor effects, especially in **KRAS-driven pancreatic cancer**. Spiclomazine functions by attenuating Ras-GTP activity and downstream RAS-mediated signaling, leading to G2 cell cycle arrest and suppression of cancer cell survival. It has demonstrated efficacy in vivo in reducing tumor progression in mouse xenograft models of pancreatic cancer[2][4][8].

Other names: clospirazineespiclomazinaspiclomazinum

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on spiclomazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spiclomazine.

Explore the full profile